Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2025-03-31 Regulatory Filings
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 100% confidence The document is a 'Total Voting Rights' announcement issued by Fusion Antibodies plc. This type of filing is a standard regulatory requirement under the FCA's Disclosure Guidance and Transparency Rules, where companies must disclose their total number of voting rights to the market. Since it does not fit into specific categories like M&A, dividends, or director dealings, and is a standard regulatory disclosure, it is classified as a Regulatory Filing (RNS).
2025-03-31 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly labeled with an 'RNS Number' and contains the header 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership (crossing thresholds) as required by regulatory bodies (like the FCA in the UK, as indicated by the RNS provider information). This directly corresponds to the definition of 'Major Shareholding Notification' (MRQ). Although it is distributed via RNS, the content itself is a specific regulatory disclosure about shareholdings, making MRQ the most precise classification over the general RNS fallback.
2025-03-24 English
Placing to raise approximately £1.17 million
Capital/Financing Update Classification · 98% confidence The document is an official announcement dated March 18, 2025, released via RNS (Regulatory News Service), indicated by the 'RNS Number : 0125B'. The core subject is a 'Placing to raise approximately £1.17 million' through the issue of new ordinary shares. This activity—raising capital through the issuance of new shares—directly corresponds to financing activities and capital structure changes. This fits the definition of 'Capital/Financing Update' (CAP). Although it involves a General Meeting (which might suggest AGM-R or PSI), the primary purpose is the capital raise itself, not the meeting agenda or voting results. Since it is a formal announcement of a specific corporate action (fundraising), CAP is the most precise classification, rather than the general fallback RNS.
2025-03-18 English
Contract win
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated February 27, 2025. It announces a 'Contract Win' regarding a new stable Cell Line Development project and provides details on expected revenue and project duration. The text concludes with standard boilerplate language referencing RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA). This structure is characteristic of a general regulatory news service announcement, which is not covered by the more specific categories like ER, IR, or CAP. Since it is a general, non-specific regulatory announcement distributed via RNS, the most appropriate fallback category is Regulatory Filings (RNS). The document length (5417 chars) is substantial enough that it is not merely an announcement *about* a report, but the report itself (a news release).
2025-02-27 English
OptiMAL R&D Update
M&A Activity Classification · 99% confidence The document starts with 'RNS Number : 3633V' and includes the standard footer information for RNS (Regulatory News Service) announcements from the London Stock Exchange. The content is a brief update titled 'R&D Update' regarding a collaboration with the National Cancer Institute (NCI) concerning the OptiMAL® platform. This is a short, timely announcement of operational progress, not a comprehensive financial report (like 10-K or IR) or a formal proxy/dividend notice. Since it is a general regulatory announcement disseminated via RNS that doesn't fit into the more specific operational/financial categories (like ER, CT, CAP, etc.), the most appropriate classification is the general regulatory filing category.
2025-01-31 English
Approval of Grant Funding Application
Earnings Release Classification · 99% confidence The document begins with an RNS Number and a date, indicating it is a regulatory announcement disseminated via a Regulatory Information Service (RNS). The content announces the 'Approval of Grant Funding Application' for Fusion Antibodies plc, detailing the non-dilutive funding secured and its purpose. This type of announcement, which conveys material, non-public information (deemed 'inside information' under MAR) to the public domain via an official news service, fits the description of a general regulatory announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), a proxy statement (DEF 14A), or a specific transaction report (DIV, DIRS, POS), the most appropriate general category for a standard regulatory news service release is RNS. FY 2024
2024-12-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.